Search

everythinglearnresearchcommunity

for

Search:↓

User experiencing hair loss on dutasteride; others suggest shedding is normal and to track progress with pictures. Some mention using RU58841 for improvement.

A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The user is seeking a knowledgeable trichologist or dermatologist in Belgium for a thorough scalp examination due to diffuse thinning and a previous diagnosis of male pattern baldness. They are interested in procedures like a trichogram and scalp biopsy.

The user has tried various treatments like Dutasteride, RU58841, Minoxidil, Finasteride, Spironolactone, Pyrilutamide, and Ketoconazole for hair loss without success and is considering a scalp biopsy to diagnose another condition. Others suggest consulting a dermatologist and possibly getting a biopsy, as the issue might not be typical male pattern baldness.

The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.

The user is experiencing a strange hair loss pattern despite using dutasteride for 3 years and minoxidil with tretinoin for 1.5 years. They recently added microneedling and are considering a scalp biopsy to understand the cause.

A 31-year-old woman experienced crown hair growth using a topical solution of finasteride (0.1%) and minoxidil (5%) over five months. She applies the solution once daily, improved her fitness, and takes vitamin D and magnesium supplements.

A 17-year-old is using topical finasteride and minoxidil for hair regrowth. The effectiveness of these treatments is discussed, with some users noting progress and others suggesting more time is needed for significant results.

Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

The conversation discusses using higher doses of minoxidil and finasteride, considering dutasteride, and exploring other treatments like RU58841 for hair preservation. The user reports no side effects after six months and is interested in advanced treatment combinations.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

The conversation discusses the effectiveness of RU58841 for hair loss compared to pyrilutamide, which failed to show significant hair regrowth in trials. Some users report personal side effects with RU58841 and question the criteria for success in hair loss treatments.

A person is seeking advice on saving their thinning crown and hairline before their wedding, currently using a topical solution with 0.1% finasteride and 7% minoxidil. They are open to trying oral treatments and are considering using Hims for convenience, with no cost concerns.

The conversation is about using finasteride and testosterone replacement therapy (TRT) for hair loss and their role in gender-affirming care. It debates whether these treatments are considered hormone replacement therapy (HRT) and their implications for both cisgender and transgender individuals.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. L'Oreal's study on Stemoxydine 5% claims a 4% increase in hair density after 3 months, but some users question potential bias.

The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.

A user's experience with early balding and their regimen of finasteride, minoxidil, microneedling, vitamin D, and biotin to treat it. Another user asked if the minoxidil had helped with regrowth before they started using it.

The user is considering switching from a stamp to a pen for hair treatment due to poor results with the stamp. They are concerned about the availability of pen refills and are seeking better outcomes with the pen.

Hair loss discussion mentions treatments Minoxidil, Finasteride, and RU58841. Verteporfin shows promise for scar/regrowth after 84 days.

People are discussing the use of an untested hair loss treatment called PP405, which is not available on the grey market. Some users are trying a mimic formulation called HP3, reporting thicker hair but no new growth yet.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

The user experienced significant hair regrowth using 5% topical minoxidil and 1mg finasteride daily, despite multiple shedding phases, and emphasizes the importance of starting treatment early and maintaining consistency. They advise against obsessing over online forums during shedding periods and recommend checking for scalp conditions like seborrheic dermatitis and ensuring proper nutrition.

The user is updating on their hair loss treatment progress after 4 months using oral finasteride, topical minoxidil spray, and weekly 1mm dermarolling. The crown area is slowly improving, with a smaller bald spot radius compared to the previous month.

The conversation is about someone observing potential hair regrowth after using finasteride/dutasteride, minoxidil, and RU58841 for almost three months. Multiple replies agree that the individual is experiencing hair regrowth.

A user is treating hair loss with Dutasteride, Minoxidil, RU58841, Derminator 2, Vitamin D, Biotin, and Zinc. After 6 months, there's no significant visual improvement, but the user feels less insecure about Retrograde Alopecia.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

The user experienced significant hairline improvement after 2 months using 1 mg Finasteride and topical Minoxidil, with only initial shedding as a side effect. The progress is notable, with the user returning from near Norwood 2 to Norwood 1, and they use Rogaine for topical application.

A compounding pharmacist offers affordable topical finasteride foam with Anagain and micro-dose finasteride capsules for hair loss. They provide telehealth services across Canada and private appointments for international patients.